PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 30(7): 1180, 2019 07 01.
Article
en En
| MEDLINE
| ID: mdl-30624609
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Ann Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2019
Tipo del documento:
Article